Matthias Thorolfsson

Title: Matthias Thorolfsson: Innovator in Immunology

Introduction

Matthias Thorolfsson is a notable inventor based in Charlottenland, Denmark. He has made significant contributions to the field of immunology, particularly in the development of human antibodies that regulate immune responses. With a total of 2 patents, his work has the potential to impact therapeutic approaches in enhancing natural killer (NK) cell activity.

Latest Patents

Thorolfsson's latest patents include innovative compositions and methods for regulating immune responses in subjects. One patent focuses on human anti-KIR antibodies that enhance NK cell cytotoxicity in mammalian subjects. This includes antibodies with antigen-binding properties similar to human monoclonal antibodies 1-7F9 or 1-4F1. Additionally, he has developed nucleic acids encoding these human anti-KIR antibodies, which also aim to increase NK cell activity or cytotoxicity in subjects.

Career Highlights

Throughout his career, Matthias Thorolfsson has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Novo Nordisk A/S and Innate Pharma S.A.S. His work in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Thorolfsson has collaborated with esteemed colleagues in the field, including Alessandro Moretta and Mariella Della Chiesa. These partnerships have further enriched his research and innovation efforts.

Conclusion

Matthias Thorolfsson stands out as an influential inventor in the realm of immunology. His patents and collaborations reflect his commitment to advancing therapeutic strategies that enhance immune responses. His contributions are poised to make a significant impact in the medical field.